Chiesi Farmaceutici S.p.a.

Daniela Cocconi

Rossella Musa

Irene Pasquali

Roberto Bilzi

Anna Maria Cantarelli

Elisa Monari

Francesca Schiaretti

Laurence Galet

Alain Chamayou

Massimiliano Dagli Alberi

Rosella Musa

Silvia Catinella

Angela Armanni

Roberto Rastelli

Andrea Busca

Compositions comprising a corticosteroid and a beta-adrenergic are useful for treating inflammatory or obstructive airways diseases.

Dry powder formulation comprising a corticosteroid and a beta-adrenergic for administration by inhalation

The invention relates to a dry powder formulation comprising corticosteroid and a beta-adrenergic drug in combination, its process preparation, and therapeutic uses thereof.

Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

Process for preparing carrier particles for dry powders for inhalation

Pharmaceutical formulations in the form of inhalable dry powder comprising particles of a phosphodiesterase-4 inhibitor as active ingredient are useful for the prevention and/or treatment of respiratory diseases, such as asthma and COPD.

Dry powder formulation comprising a phosphodiesterase inhibitor

Dry powder formulations comprising a corticosteroid and a beta-adrenergic drug in combination are useful for the prevention and/or treatment of inflammatory or obstructive airways diseases.

Micronized particles of a low-dosage strength active ingredient, to be used in dry powder formulations for inhalation, with particular properties can easily and homogenously disperse in a dry powder formulation to be administered by means of a dry powder inhaler device.

Micronized particles of low-dosage strength active agents for powder formulations for inhalation

The invention provides a formulation to be administered as dry powder for inhalation suitable for efficacious delivery of low-dosage strength active ingredients to the low respiratory tract of patient. In particular, the invention provides a formulation comprising microparticles constituted of microparticles of a low-dosage strength active ingredient and microparticles of an excipient wherein the MMD of the microparticles is comprised between 2 and 15 micron, at least 10% of the microparticles has a mass diameter (MD) higher than 0.5 micron, and the process of preparation thereof.

Growing community of inventors

Parma, Italy

Daniela Cocconi